Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

• Status: Completed
• Trial end date: 2016-09-19
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see whether or not the combination of cisplatin, irinotecan and radiation, followed by surgery, followed by oral Sutent, is effective and safe for patients with resectable esophageal cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto
• Collaborator: Pfizer
• Treatments: Cisplatin; Irinotecan; Sunitinib

Criteria

Inclusion Criteria:

• Histologically proven squamous or adenocarcinoma or the esophagus >20 cm from the incisors, including GE junction tumors (unless of gastric origin).

• Tumors must be technically resectable.

• Clinical T1N1M0, T2-3 N0-1 M0

• Performance status ECOG 0-1

• Medically fit for chemotherapy, radiation and esophagectomy

Exclusion Criteria:

• In situ or clinical T1N0M0, and stage IV (M1a orM1b)

• Cervical esophageal tumors (within 20 cm of the incisors)

• Age <18 or >70

• Participation in another concurrent clinical study involving study drug(s) or treatment with study drug within thirty days prior to the treatment on this study. Concurrent treatment with other experimental drugs or anticancer therapy

• known or suspected drug or alcohol abuse

• Prior treatment for this malignancy except esophageal stenting